Dr. Reddy's

1. AstraZeneca Slaps Sun Pharma Over Nexium IV Generic

Tuesday, Mar 02, 2010

AstraZeneca AB has hit generic-drug maker Sun Pharma Global Inc. with a patent suit over its plan to market a generic formulation of AstraZeneca’s intravenous acid reflux disease treatment Nexium IV.

2. Allegra Suits Dropped After Sandoz Amends ANDAs

Tuesday, Feb 23, 2010

Aventis Pharmaceuticals Inc. and Albany Molecular Research Inc. have dropped six patent infringement suits against Sandoz Inc. over the allergy drug Allegra, following Sandoz's amendment of two abbreviated new drug applications to seek approval for generic versions only after the applicable patents expire.

3. AstraZeneca, Teva Settle Heartburn Drug Patent Suits

Thursday, Jan 07, 2010

AstraZeneca AB and Teva Pharmaceuticals Ltd. have settled patent litigation over the Israeli generic-drug maker's versions of blockbuster heartburn medications Nexium and Prilosec, according to the companies.

4. Dr. Reddy's Loses Zyprexa Patent Fight In UK Court

Friday, Dec 18, 2009

A U.K. appeals court has upheld the validity of Eli Lilly & Co.'s patent for Zyprexa, rejecting Dr. Reddy's Laboratories Ltd.'s contention that an earlier Lilly patent rendered the patent for the blockbuster schizophrenia drug invalid.

5. Generics Maker Says Drug-Safety Program Gets Abused

Friday, Nov 13, 2009

Teva Pharmaceuticals Ltd. has reportedly complained to the Federal Trade Commission that it has been unable to purchase bulk quantities of certain pharmaceuticals because brand-name drug companies are using a federal drug-safety program to unfairly limit competition.

6. India, Brazil Prepare WTO Action Over EU Drug Seizures

Thursday, Oct 22, 2009

India and Brazil are reportedly on the verge of launching a formal complaint with the World Trade Organization as part of a long-simmering battle with the European Union over the frequent seizure of generic drugs at European ports over alleged patent violations.

7. Patent Suit Ends After Lupin Acquires Antara Rights

Monday, Oct 05, 2009

Oscient Pharmaceuticals Corp. and Ethypharm SA have dropped a patent infringement suit they brought against Lupin Ltd. over the cholesterol drug Antara, less than two weeks after Lupin announced that it had acquired the U.S. rights to Antara from bankrupt Oscient for nearly $39 million.

8. Novartis, 2 Generics Drop Lotrel Patent Lawsuits

Friday, Sep 25, 2009

Novartis AG and two generic-drug makers have agreed to dismiss without prejudice a total of four patent lawsuits in which the U.S. arm of the Switzerland-based pharmaceutical giant had said applications to make generic versions of the hypertension drug Lotrel infringed its patent.

9. Sandoz, Dr. Reddy's Sued Over Allegra Patent

Tuesday, Sep 15, 2009

Albany Molecular Research Inc. has hit Dr. Reddy's Laboratories Inc. and Sandoz Inc. with a lawsuit, accusing the two of infringing a patent used in Sanofi-Aventis' Allegra.

10. Schering, Orchid Settle Clarinex Patent Suit

Wednesday, Aug 12, 2009

Orchid Chemicals & Pharmaceuticals Ltd. and its subsidiary Orgenus Pharma Inc. have reached an agreement with Schering-Plough Corp. that will allow Orchid to bring two generic versions of Schering's allergy drug Clarinex to the U.S. market in 2012.

11. India To Launch WTO Battle Over EU Drug Seizures

Thursday, Aug 06, 2009

A battle is brewing between the European Union and India, which reportedly plans to complain to the World Trade Organization about the frequent seizure of Indian generic drugs at European ports over alleged patent violations.

12. Q&A With Paul Hastings' Joseph O’Malley

Thursday, Jul 02, 2009

The defense of inequitable conduct needs reform, as the standard for proving the defense is perceived by many in the patent bar as being applied somewhat inconsistently right now at the Federal Circuit, says Joseph M. O’Malley Jr., chair of Paul Hastings Janofsky & Walker LLP's intellectual property practice.

13. Teva, Zydus Reach Settlement Over Coreg Patents

Thursday, May 14, 2009

Teva Pharmaceutical Industries Ltd. has settled a lawsuit with Zydus Pharmaceuticals Inc. and Cadila Healthcare Ltd. over a patented process for making the key ingredient in the heart-failure treatment Coreg.

14. Sepracor Lied To USPTO In Lunesta Patent App: Suit

Monday, May 04, 2009

Indian pharmaceutical company Wockhardt Inc. has fired back in a patent infringement suit over proposed generic versions of blockbuster sleep drug Lunesta, alleging that the drug’s maker, Sepracor Inc., deliberately misled the U.S. Patent and Trademark Office.

15. Sepracor Sues Mylan Over Generic Lunesta Plans

Thursday, Apr 23, 2009

Pharmaceutical company Sepracor Inc. has sued rival Mylan Inc. for seeking to make a generic version of Sepracor's insomnia drug Lunesta, which Sepracor claims would infringe its patents.

16. Teva, Glenmark Resolve Spat Over Coreg Patents

Tuesday, Apr 21, 2009

Teva Pharmaceutical Industries Ltd. and Glenmark Pharmaceuticals Ltd. have agreed to dismiss claims and counterclaims of patent infringement and federal antitrust law violations in a lawsuit over two of Teva's patents related to congestive heart failure treatment Coreg.

17. Schering, Mylan Settle Generic Clarinex Patent Case

Wednesday, Apr 08, 2009

Mylan Pharmaceuticals Inc. and Schering Corp. have reached an agreement in patent litigation over Clarinex that will allow the generics maker to begin selling a copycat version of the allergy medicine in July 2012.

18. Sepracor Sues Generics Makers Over Lunesta Patents

Monday, Mar 23, 2009

Pharmaceutical company Sepracor Inc. has lodged a patent infringement suit against several companies, including Teva Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Inc., that are seeking to make generic versions of the blockbuster sleep drug Lunesta.

19. FTC Declines To Challenge Reverse Payment Deal

Friday, Mar 20, 2009

The Federal Trade Commission has disclosed that it will not challenge a so-called reverse payment agreement between generic-drug makers Mylan Inc., Dr. Reddy’s Laboratories Inc. and Cobalt Pharmaceuticals Inc. on one side and Keppra maker UCB SA on the other.

20. Schering Merger Includes Legal Headaches For Merck

Monday, Mar 09, 2009

As Merck & Co. prepares to join forces with Schering-Plough Co. in a $41.1 billion deal, the drugmaker stands ready to inherit a host of legal problems — including antitrust, employment, intellectual property and product liability suits — right along with an expanded arsenal of drugs and medical technology.